Company news
Hanmi Pharmaceutical Co., Ltd. news in 2025
Hanmi Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
December 19, 2025
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
November 19, 2025
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
September 29, 2025
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
September 22, 2025
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
August 22, 2025
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
July 15, 2025
Aptose Announces Deferral of Interest Payment
June 30, 2025
Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion
April 2, 2025